Details for New Drug Application (NDA): 008693
✉ Email this page to a colleague
NDA 008693 describes FURADANTIN, which is a drug marketed by Casper Pharma Llc and Procter And Gamble and is included in two NDAs. It is available from two suppliers. Additional details are available on the FURADANTIN profile page.
The generic ingredient in FURADANTIN is nitrofurantoin. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the nitrofurantoin profile page.
The generic ingredient in FURADANTIN is nitrofurantoin. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the nitrofurantoin profile page.
Summary for 008693
| Tradename: | FURADANTIN |
| Applicant: | Procter And Gamble |
| Ingredient: | nitrofurantoin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 008693
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
